doi:10.3969/j.issn.1004-583X.2021.11.014

Abstract

CLC Number:

R587.24

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.11.014

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I11/1029

References 41

[1]	Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF diabetes atlas: Global estimates for the prevalence of diabetes for 2015 and 2040[J]. Diabetes Res Clin Pract, 2017, 128:40-50. doi: 10.1016/j.diabres.2017.03.024 URL
[2]	Umanath K, Lewis JB. Update on diabetic nephropathy: Core curriculum 2018[J]. Am J Kidney Dis, 2018, 71(6):884-895. doi: S0272-6386(17)31102-2 pmid: 29398179
[3]	Kittiskulnam P, Sheshadri A, Johansen KL. Consequences of CKD on functioning[J]. Semin Nephrol, 2016, 36(4):305-318. doi: 10.1016/j.semnephrol.2016.05.007 pmid: 27475661
[4]	Mendes R, Martins S, Fernandes L. Adherence to medication, physical activity and diet in older adults with diabetes: Its association with cognition, anxiety and depression[J]. J Clin Med Res, 2019, 11(8):583-592. doi: 10.14740/jocmr3894 pmid: 31413770
[5]	Huang M, Liu Y, Wang J, et al. High rates of depression anxiety and suicidal ideation among inpatients in general hospital in China[J]. Int J Psychiatry Clin Pract, 2019, 23(2):99-105. doi: 10.1080/13651501.2018.1539179 URL
[6]	Stanton R, Rosenbaum S, Rebar A, et al. Prevalence of chronic health conditions in Australian adults with depression and/or anxiety[J]. Issues Ment Health Nurs, 2019, 40(10):902-907. doi: 10.1080/01612840.2019.1613701 URL
[7]	熊莉, 马文. 慢性阻塞性肺疾病合并焦虑、抑郁的诊断及治疗进展[J]. 疑难病杂志, 2021, 20(11):1173-1177.
[8]	Rees G, Xie J, Fenwick EK, et al. Association between diabetes-related eye complications and symptoms of anxiety and depression[J]. JAMA Ophthalmol, 2016, 134(9):1007-1014. doi: 10.1001/jamaophthalmol.2016.2213 URL
[9]	Khaledi M, Haghighatdoost F, Feizi A, et al. The prevalence of comorbid depression in patients with type 2 diabetes: An updated systematic review and meta-analysis on huge number of observational studies[J]. Acta Diabetol, 2019, 56(6):631-650. doi: 10.1007/s00592-019-01295-9 URL
[10]	Pan S, Liu ZW, Shi S, et al. Hamilton rating scale for depression-24 (HAM-D24) as a novel predictor for diabetic microvascular complications in type 2 diabetes mellitus patients[J]. Psychiatry Res, 2017, 258:177-183. doi: 10.1016/j.psychres.2017.07.050 URL
[11]	Sharif S, Raza MT, Mushtaq S, et al. Frequency of depression in patients with type 2 diabetes mellitus and its relationship with glycemic control and diabetic microvascular complications[J]. Cureus, 2019, 11(7):e5145.
[12]	Zhang L, Long J, Jiang W, et al. Trends in chronic kidney disease in China[J]. N Engl J Med, 2016, 375(9):905-906. doi: 10.1056/NEJMc1602469 URL
[13]	Mosleh H, Alenezi M, Al Johani S, et al. Prevalence and factors of anxiety and depression in chronic kidney disease patients undergoing hemodialysis: A cross-sectional single-center study in Saudi Arabia[J]. Cureus, 2020, 12(1):e6668. doi: 10.7759/cureus.6668 pmid: 31976185
[14]	Chan KM, Cheung CY, Chan YH, et al. Prevalence and impact of anxiety and depression in Chinese peritoneal dialysis patients: A single centre study[J]. Nephrology (Carlton), 2018, 23(2):155-161. doi: 10.1111/nep.2018.23.issue-2 URL
[15]	Unsal Avdal E, Ayvaz I, Özgursoy Uran BN, et al. Opinions of hemodialysis and peritoneum patients regarding depression and psychological problems which they experience: A qualitative study[J]. J Infect Public Health, 2020, 13(12):1988-1992. doi: 10.1016/j.jiph.2020.02.041 URL
[16]	Shirazian S, Grant CD, Aina O, et al. Depression in chronic kidney disease and end-stage renal disease: Similarities and differences in diagnosis, epidemiology, and management[J]. Kidney Int Rep, 2016, 2(1):94-107.
[17]	Cohen SD, Cukor D, Kimmel PL. Anxiety in patients treated with hemodialysis[J]. Clin J Am Soc Nephrol, 2016, 11(12):2250-2255. doi: 10.2215/CJN.02590316 URL
[18]	Pu L, Zou Y, Wu SK, et al. Prevalence and associated factors of depressive symptoms among chronic kidney disease patients in China: Results from the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE)[J]. J Psychosom Res, 2020, 128:109869.
[19]	Sun N, Lou P, Shang Y, et al. Prevalence and determinants of depressive and anxiety symptoms in adults with type 2 diabetes in China: A cross-sectional study[J]. BMJ Open, 2016, 6(8):e012540.
[20]	Takasaki K, Babazono T, Ishizawa K, et al. Relationship between diabetic nephropathy and depression: A cross-sectional analysis using the Diabetes Study from the Center of Tokyo Women's Medical University (DIACET)[J]. BMJ Open Diabetes Res Care, 2016, 4(1):e000310.
[21]	Aggarwal HK, Jain D, Dabas G, et al. Prevalence of depression, anxiety and insomnia in chronic kidney disease patients and their co-relation with the demographic variables[J]. Pril (Makedon Akad Nauk Umet Odd Med Nauki), 2017, 38(2):35-44. doi: 10.1515/prilozi-2017-0020 pmid: 28991772
[22]	Zheng G, Wen J, Lu H, et al. Elevated global cerebral blood flow, oxygen extraction fraction and unchanged metabolic rate of oxygen in young adults with end-stage renal disease: An MRI study[J]. Eur Radiol, 2016, 26(6):1732-1741. doi: 10.1007/s00330-015-3968-9 pmid: 26334507
[23]	Loosman WL, Rottier MA, Honig A, et al. Association of depressive and anxiety symptoms with adverse events in Dutch chronic kidney disease patients: A prospective cohort study[J]. BMC Nephrol, 2015, 16:155. doi: 10.1186/s12882-015-0149-7 pmid: 26390864
[24]	Adibfar A, Saleem M, Lanctot KL, et al. Potential biomarkers for depression associated with coronary artery disease: A critical review[J]. Curr Mol Med, 2016, 16(2):137-164. pmid: 26812919
[25]	Lampropoulou IT, Stangou M, Sarafidis P, et al. TNF-α pathway and T-cell immunity are activated early during the development of diabetic nephropathy in type II diabetes mellitus[J]. Clin Immunol, 2020, 215:108423.
[26]	Simões E Silva AC, Miranda AS, Rocha NP, et al. Neuropsychiatric disorders in chronic kidney disease[J]. Front Pharmacol, 2019, 10:932. doi: 10.3389/fphar.2019.00932 URL
[27]	Deschênes SS, Burns RJ, Schmitz N. Comorbid depressive and anxiety symptoms and the risk of type 2 diabetes: Findings from the lifelines cohort study[J]. J Affect Disord, 2018, 238:24-31. doi: 10.1016/j.jad.2018.05.029 URL
[28]	Goh ZS, Griva K. Anxiety and depression in patients with end-stage renal disease: Impact and management challenges-A narrative review[J]. Int J Nephrol Renovasc Dis, 2018, 11:93-102. doi: 10.2147/IJNRD URL
[29]	Tafet GE, Nemeroff CB. Pharmacological treatment of anxiety disorders: The role of the HPA axis[J]. Front Psychiatry, 2020, 11:443.
[30]	Huo R, Zeng BH, Zeng L, et al. Microbiota modulate anxiety-like behavior and endocrine abnormalities in hypothalamic-pituitary-adrenal axis[J]. Front Cell Infect Microbiol, 2017, 7:489. doi: 10.3389/fcimb.2017.00489 URL
[31]	Diaz Bustamante L, Ghattas KN, Ilyas S, et al. Does treatment for depression with collaborative care improve the glycemic levels in diabetic patients with depression? A systematic review[J]. Cureus, 2020, 12(9):e10551.
[32]	Zahed NS, Sharifi M, Karimi M, et al. Impact of sertraline on serum concentration of CRP in hemodialysis patients with depression[J]. J Renal Inj Prev, 2016, 6(1):65-69. doi: 10.15171/jrip.2017.12 URL
[33]	Yuan P, Zhang J, Li L, et al. Fluoxetine attenuated anxiety-like behaviors in streptozotocin-induced diabetic mice by mitigating the inflammation[J]. Mediators Inflamm, 2019, 2019:4315038.
[34]	Kessing LV, Rytgaard HC, Ekstrøm CT, et al. Antidiabetes agents and incident depression: A nationwide population-based study[J]. Diabetes Care, 2020, 43(12):3050-3060. doi: 10.2337/dc20-1561 pmid: 32978179
[35]	Wyska E. Pharmacokinetic considerations for current state-of-the-art antidepressants[J]. Expert Opin Drug Metab Toxicol, 2019, 15(10):831-847. doi: 10.1080/17425255.2019.1669560 URL
[36]	Natale P, Palmer SC, Ruospo M, et al. Psychosocial interventions for preventing and treating depression in dialysis patients[J]. Cochrane Database Syst Rev, 2019, 12(12): CD004542.
[37]	Powers MB, de Kleine RA, Smits JAJ. Core Mechanisms of Cognitive Behavioral Therapy for Anxiety and Depression: A Review[J]. Psychiatr Clin North Am, 2017, 40(4):611-623. doi: 10.1016/j.psc.2017.08.010 URL
[38]	Valsaraj BP, Bhat SM, Latha KS. Cognitive behaviour therapy for anxiety and depression among people undergoing haemodialysis: A randomized control trial[J]. J Clin Diagn Res, 2016, 10(8): VC06-VC10.
[39]	Chan R, Dear BF, Titov N, et al. Examining internet-delivered cognitive behaviour therapy for patients with chronic kidney disease on haemodialysis: A feasibility open trial[J]. J Psychosom Res, 2016, 89:78-84. doi: 10.1016/j.jpsychores.2016.08.012 URL
[40]	Armani Kian A, Vahdani B, Noorbala AA, et al. The impact of mindfulness-based stress reduction on emotional wellbeing and glycemic control of patients with type 2 diabetes mellitus[J]. J Diabetes Res, 2018, 2018:1986820.
[41]	Zhu FX, Zhang XY, Ding XK, et al. Protective effect of regular physical activity on major depressive episodes in patients with early stages of chronic kidney disease[J]. Ren Fail, 2017, 39(1):602-606. doi: 10.1080/0886022X.2017.1361833 URL

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 41

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. [J]. Clinical Focus, 2023, 38(6): 564-568.
[2]	Li Huifang, Miao Xia. Prediction of thyroid hormone level on risk of type 2 diabetes nephropathy [J]. Clinical Focus, 2023, 38(2): 137-142.
[3]	He Feng, Nin Lu, Luo Gao, Yang Ruifei, Li Fanfan, Cheng Xiaoqiong, An Binbin, Li Jingjuan, Liu Yuanyuan, Guo Qian, Wang Jinyang. Correlation of Chinese visceral adipose index and visceral fat area with diabetic nephropathy and their warning values [J]. Clinical Focus, 2022, 37(12): 1089-1093.
[4]	Yao Yao, Chu Min. Relationship between serum amyloid β-protein and cognitive dysfunction in patients with diabetic kidney disease [J]. Clinical Focus, 2022, 37(9): 813-816.
[5]	. [J]. Clinical Focus, 2022, 37(5): 467-471.
[6]	Gao Shixin, Song Bing, Shi Kexin. Diagnosis value of serum lipoprotein α, cystatin-C and uric acid on early diabetic nephropathy [J]. Clinical Focus, 2022, 37(3): 248-252.
[7]	. [J]. Clinical Focus, 2022, 37(2): 178-181.
[8]	Liu Lunzhi, Deng Lu, Zhang Mingxia. Effects of angiotensin Ⅱ type 1 receptor blockers on urinary nephrin and Beclin-1 mRNA excretion in urine of patients with early diabetic nephropathy [J]. Clinical Focus, 2021, 36(11): 1005-1008.
[9]	. [J]. Clinical Focus, 2021, 36(11): 1034-1040.
[10]	Liu Meng, Hu Guicai, Yang Zongna, Guo Weiwei, Chen Wanxin. Comparative study on volume load and nutritional status in hemodialysis patients with diabetic kidney disease and non-diabetic kidney disease [J]. Clinical Focus, 2021, 36(4): 332-335.
[11]	Wang Chunhua. Effect of alprostadil combined with Sanqi Panax Notoginseng Injection on proteinuria in early diabetic nephropathy [J]. Clinical Focus, 2015, 30(12): 1410-1412.
[12]	. [J]. Clinical Focus, 2015, 30(6): 715-717718.
[13]	ZHANG Chang-qin;LUO Yang. Curative effect of torasemide on diabetic nephrotic edema [J]. Clinical Focus, 2014, 29(9): 1002-1004.
[14]	ZHOU Bin;ZHOU Ying-li;FU Yu;SHI Peng;LIN Wei-min;CAO Jia-yue. Effect of alprostadil combined with Shenmai or astragalus in treatment of diabetic nephropathy [J]. Clinical Focus, 2014, 29(7): 724-727.
[15]	. [J]. Clinical Focus, 2014, 29(7): 814-815.